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Hexachloroethane/zinc oxide (HC/ZnO)
smoke, also known as white smoke, has
many military and civilian applications, such
as in training exercises and on the battleﬁeld
[Agency for Toxic Substances and Disease
Registry (ATSDR) 1997; Holmes 1999;
Zerahn et al. 1999]. Inhalation is the most
common route of injury. Documented
injuries are predominately pulmonary and
range from cough and dyspnea to chemical
pneumonitis, pulmonary edema, adult res-
piratory distress syndrome, and death
(Cullumbine 1957; Greenfield et al. 2002;
Hjortso et al. 1988). The toxicity of HC/ZnO
smoke results from both the chemical and
physical properties of the smoke. The primary
component of white smoke is HC/ZnO com-
bined with granular aluminum. Upon burn-
ing, several compounds are produced: zinc
chloride, 62.5%; ZnO, 9.6%; iron oxide,
10.7%; aluminum oxide, 5.4%; lead oxide,
1%; and chlorinated vapors, 10.8% (DeVaull
et al. 1989). The reaction equation is as fol-
lows (Cichowicz 1983):
2 Al + C2Cl6 + 3 ZnO →
3 ZnCl2 + Al2O3 + 2 C + heat.
The reaction is exothermic and self-
perpetuating to the right, liberating large
amounts of ZnCl2 as a hot vapor. Upon cool-
ing, it nucleates to form an aerosol that
rapidly absorbs water from the surrounding
atmosphere. Hydrated ZnCl2 particles then
scatter light, thereby creating the desired
obscurant effect (ATSDR 1997; Holmes
1999; Katz et al. 1980). When a smoke
grenade is used, the heat causes other chemi-
cals to form, including carbon tetrachloride,
tetrachlorethylene, hexachlorobenzene, and
phosgene (ATSDR 1997). Medical personnel,
military and civilian alike, may be called upon
to recognize and treat patients with HC/ZnO
smoke injuries. Almost all studies have
focused on the pulmonary effects, and little if
any information exists on hepatic toxicity. In
this article we report two cases of acute
hepatic injuries associated with HC/ZnO
smoke inhalation.
Case Reports
Patient 1. The ﬁrst patient, a 23-year-old man
with an unremarkable medical and surgical
history, was admitted to our hospital because
of accidental inhalation of HC/ZnO smoke
during military training. The patient had been
healthy previously and denied any history of
alcohol or drug abuse. This soldier speciﬁcally
denied any history of smoking or pulmonary
disorders. He had been in a tunnel without
respiratory protection when a smoke grenade
used to simulate battle conditions ignited near
the entrance. The tunnel was about 1.75 m ×
0.6 m × 360 m (5.74 ft × 1.97 ft × 1,181 ft).
The estimated time of exposure to the
HC/ZnO smoke was about 3 min. He
suffered from lacrimation, cough, chest tight-
ness, dyspnea, and sore throat at the scene. 
On arrival at the hospital, the initial physi-
cal examination showed that the patient’s
blood pressure was 110/70 mmHg, his heart
rate was 80 bpm, and his oral temperature was
38.1°C (100.6°F). His respirations were shal-
low but unlabored, with a rate of 19/min.
Auscultation of the lungs was unremarkable.
The cardiac examination revealed a normal S1
and S2 without murmur, gallop, rub, or click.
Arterial blood gas analysis and blood chemistry
test values were within the normal ranges
except that the alanine aminotransferase (ALT)
and γ-glutamyl transpeptidase (GGT) levels
were elevated about 1.5-fold of normal limits
and the aspartate aminotransferase (AST) level
was marginally elevated. Leukocytosis with
neutrophils predominating was also noted
(Table 1). The leukocytosis returned to normal
on the 10th day after the event. 
He was admitted to the pulmonary ward
for observation. Oxygen (6 L/min) was deliv-
ered by mask after admission. Exacerbation of
his respiratory condition developed on the
third day in the hospital. Chest auscultation
revealed bilateral basal crackles. Radiography
of the chest showed interstitial pulmonary
inﬁltration in both lower lungs. Intravenous
hydrocortisone (600 mg/day) and a prophy-
lactic antibiotic (ceftazidime 1 g every 8 hr
for 5 days) were administered. His respiratory
condition improved after steroid therapy.
The steroid dose was decreased gradually
and discontinued 13 days after initiation.
Elevation of liver enzymes was noted during
hospitalization. ALT levels increased to
138 U/L on day 7 and peaked at 625 U/L on
day 22 (Figure 1). Serologic investigation was
negative for viral hepatitis B and C. No sig-
niﬁcant abnormal ﬁndings were observed on
abdominal sonography. 
The patient was discharged on the 28th
hospital day with a decreasing liver enzyme
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CONTEXT: We report on two patients, a 23-year-old man and a 24-year-old man, who had chemical
pneumonitis and respiratory distress after inhaling hexachloroethane/zinc oxide (HC/ZnO) smoke
during military training.
CASE PRESENTATION: The patients had been healthy previously and denied any history of alcohol or
drug abuse. Hematologic tests revealed leukocytosis with neutrophils predominant. The respiratory
conditions of both patients improved after steroid therapy and oxygen support, but deterioration
of liver function was found. The laboratory results showed that alanine aminotransferase (ALT)
and γ-glutamyl transpeptidase levels were elevated about 1.5-fold the normal limits and that aspar-
tate aminotransferase (AST) levels were marginally elevated. The elevation of liver amino-
transferase started from day 1 and day 2 and peaked from day 18 to day 22. ALT/AST levels then
returned to normal in 6 weeks. Common viral hepatitis was ruled out after serologic tests.
Abdominal sonography and physical examination failed to show any speciﬁc ﬁndings. 
DISCUSSION: The hepatotoxic effect was attributed to inhalation of high-concentration HC/ZnO
smoke in an enclosed area, where several hepatotoxicants, including ZnCl2, HC, and chlorinated
vapors, could have been generated and mixed in the smoke. 
RELEVANCE TO CLINICAL PRACTICE. These case reports elaborate the hepatic effects that may occur
in addition to pulmonary effects of HC/ZnO smoke.
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Research | Environmental Medicinelevels. Two weeks later (6 weeks after the acci-
dent), the patient’s liver function returned to
normal. In addition, in serial follow-up studies
we failed to ﬁnd any evidence of HIV (human
immunodeficiency virus) or autoimmune
disease for 18 months.
Patient 2. The second patient, a 24-year-
old man with an unremarkable medical his-
tory, was admitted to our hospital on the
same day from the same accident described
for patient 1. He had been healthy previously
and denied any history of alcohol or drug
abuse. He also had dyspnea, cough, chest dis-
tress, and a sore throat. Physical examination
revealed blood pressure of 120/74 mmHg,
heart rate of 84 bpm, and oral temperature of
37.4°C (99.3°F). Arterial blood gas analysis
and blood chemistry tests were within the
normal ranges. Hematologic tests revealed
leukocytosis with neutrophils predominant
(Table 1). The leukocytosis returned to nor-
mal on the 9th day after the event. 
Oxygen was given by face mask after
admission. Two days later, the patient experi-
enced progressive respiratory distress. Chest
auscultation revealed bilateral expiratory
wheezes. A chest radiograph revealed diffuse
interstitial infiltrates. High-resolution com-
puted tomography of the chest showed acute
inhalation pneumonitis with patchy and small
ill-deﬁned nodular areas of ground-glass opac-
ity over all lung ﬁelds. Respiratory supports,
including steroid therapy and antibiotic pro-
phylaxis were administered as for patient 1.
Three days after treatment, his respiratory
condition improved and we began to gradu-
ally decrease the steroid. 
The AST and ALT concentrations
increased to a peak of 92 and 195 U/L, respec-
tively, on day 18 (Figure 1). Serologic tests for
hepatitis B and C and abdominal sonography
showed no abnormal ﬁndings. The ALT level
decreased to 95 U/L before discharge on the
27th day. Two weeks after discharge, the
patient’s liver function returned to normal. In
addition, serial follow-up studies failed to ﬁnd
any evidence of HIV or autoimmune disease
for 18 months.
Discussion
HC/ZnO smoke is used by the military to
conceal troops, for crowd dispersal, and occa-
sionally in military and civilian fire-fighting.
The acute toxic effects of HC/ZnO smoke on
the respiratory tract are primarily attributed
to inhalation of hydrated ZnCl2 vapor. The
vapor is very corrosive and rapidly damages
the respiratory mucosal surface (Cullumbine
1957; Greenfield et al. 2002; Hjortso et al.
1988). To the best of our knowledge, the
hepatic effects of HC/ZnO are very limited.
Pettila et al. (2000) reported three patients
with ZnCl2 inhalation; all three patients had
severe acute respiratory distress syndrome
(ARDS). Acute exposure causes the elevation
of liver enzymes by day 1 or 2, which peaks
from day 18 to day 21 and then returns to
normal in 6 weeks (Figure 1). The mecha-
nism of hepatotoxicity of HC/ZnO smoke is
still unknown. Several compounds, including
ZnO, ZnCl2, HC, chlorinated vapors, and
medications, may cause hepatic toxicity.
ZnO has not been reported to cause
hepatic damage, whereas ZnCl2, HC, and
chlorinated compounds have great potential
to induce hepatotoxicity. Among 12 workers
with 4–21 years of exposure to ZnO fumes in
the production of brass alloys, no liver disease
was reported (ATSDR 2003b; Hamdi 1969).
Pettila et al. (2000) reported abnormal liver
function (ALT of 119, 131, and 2,570 U/L)
in three patients; however, because there was
no detailed personal history (e.g., transfusion,
alcohol consumption) or viral markers, it was
difﬁcult to evaluate the potential hepatotoxic-
ity. Marrs et al. (1988) observed a signiﬁcant
increase in the incidence of fatty liver in mice
after repeated exposure to ZnCl2 smoke, but
the incidence did not increase with the dose,
and hepatic toxicity was not observed in the
liver of rats and guinea pigs using the same
exposure paradigm.
About 5% or less of the compounds in
HC/ZnO smoke are released into the air as
HC. In one study, Selden et al. (1993)
reported that liver function tests were not
affected in HC-exposed workers who wore
protective clothing. Animal studies have shown
that hepatic tissues are moderately vulnerable
to HC exposure, especially when exposure
occurs by the oral route. Increases in liver
weight, increases in serum levels of liver
enzymes, centrilobular necrosis, fatty degenera-
tion, hemosiderin-laden macrophages, and
hemorrhage were seen in animals exposed to
HC [ATSDR 1997; Fowler 1969; Gorzinski
1985; National Toxicology Program (NTP)
1989; Weeks et al. 1979]. In these studies,
effects on the liver and kidneys were mild with
inhalation exposure and more pronounced
with oral exposure. In a study of acute and
intermediate-duration inhalation exposure, the
only effect noted by Weeks et al. (1979) after
6 weeks of exposure to 260 ppm HC was an
increase in liver weight in rats and guinea pigs
but not in quail.
About 10% of HC/ZnO smoke is com-
posed of chlorinated compounds (Holmes
1999; Katz et al. 1980; National Research
Council 1997). The chlorinated compounds
include tetrachloromethane (i.e., carbon tetra-
chloride, CCl4), tetrachloroethylene, and
hexachlorobenzene. CCl4 has long been
known to be a powerful hepatotoxic agent in
humans and animals. The principal clinical
signs of liver injury in humans who inhale
CCl4 are a swollen and tender liver, elevated
levels of hepatic enzymes in serum, elevated
serum bilirubin levels and the appearance of
jaundice, and decreased serum levels of pro-
teins such as albumin and ﬁbrinogen (ATSDR
2003a). Liver necrosis was reported in one fatal
case involving an alcoholic patient who was
exposed to 250 ppm for 15 min (Norwood et
al. 1950). High CCl4 vapor concentration
might have produced liver injury in our
patients. However, we could not identify any
right upper quadrant tenderness or liver
enlargement in either of our patients.
Toxicant- or drug-induced liver injury is a
potential complication of nearly every medi-
cation (Lee 1995). We needed to rule out the
possibility that the observed hepatic toxicity
was due to therapeutic drugs. For our cases, we
prescribed acetaminophen for fever, steroids,
antibiotics, bambuterol, aminophylline, iprat-
ropium, mucolytics for pulmonary symptoms,
and a mild sedative for sleeping. The three
potential hepatic toxicants are acetaminophen,
steroids, and antibiotics; however, aceta-
minophen taken at recommended doses
(0.5–3 g daily) is relatively safe (Norris 2000).
One of our cases took < 0.5 mg/day for 2 days,
and the other never took it. 
Steroid therapy is a standard treatment of
ARDS and is applied universally. A thorough
Loh et al.
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Table 1. Characteristics and biochemical data of
patients 1 and 2 at 4 hr after the event.
Normal range
Patient 1 Patient 2 for males
Age (years) 23 24
Body weight (kg) 64.5 67
Body mass index 19  21  18–24
(kg/m2) 
White blood cell  21,900 17,100 4,500–11,000
(L/mm3) 
Neutrophils (%) 93 91  40–70
Lymphocytes (%) 3.8 3.4 19–48
ALT (U/L) 60 24  < 41
AST (U/L) 47 31  < 37
ALP (U/L) 176 123  40–129
GGT (U/L) 61 25  9–40
ALP, alkaline phosphatase.  Figure 1. Changes in ALT levels of patients 1 and 2.
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search of the literature revealed only a few
case reports of suspected corticosteroid-
induced hepatomegaly (Nanki et al. 1999).
Based on limited data, it is difﬁcult to justify
any correlation between corticosteroid use
and the hepatitis seen in our patients. 
Elevations in liver enzymes and bilirubin
have occurred during treatment with cef-
tazidime. The incidence appears similar to
that with other cephalosporins (Meyers 1985).
In most cases, liver enzyme elevations have
been transient, with levels returning to normal
after withdrawal of treatment. Our patients
received a 5-day course of ceftazidime for pro-
phylaxis. However, continued deterioration of
liver function was observed after ceftazidime
was discontinued. 
The diagnosis of toxicant-induced liver
injury is often obscured by difficulty in
determining the precise timing of toxicant
ingestion and lack of speciﬁc symptoms (Lee
1995; Norris 2000). Central to the diagnosis
is a thorough history, including drug expo-
sure and occupational hazards with exposure
to chemicals. In addition, the changes of
liver enzymes may represent progression on
underlying disease, a complication of the
underlying disease, or an unrelated episode,
such as sepsis or shock (Norris 2000).
Confirmation of the diagnosis by a toxicant
rechallenge is reliable but rarely justifiable
(Lee 1995; Maria et al. 1997; Norris 2000).
However, given that these two individuals
inhaled the same gas, it is more likely that
the effects were due to either the chemicals
in the smoke or a combination of the chemi-
cals in the smoke and the drugs, rather than
the drugs alone.
The main treatment for toxicant-induced
hepatotoxicity is the withdrawal or removal of
the agent, supportive care, and alleviation of
the symptoms (Lee 1995; Norris 2000). In
our cases, there was no treatment beyond what
was done for the respiratory effects.
Conclusion
Inhalation of HC/ZnO smoke may have
hepatic effects in addition to the effect of pul-
monary distress. The hepatotoxic effect in our
patients was attributed to inhalation of high-
concentration HC/ZnO smoke in an enclosed
area, where several compounds including
ZnCl2, HC, and chlorinated vapors may have
been generated and mixed in the smoke.
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